Concentrate safety and efficacy (Q34636847)

3 August 2017

1 reference

title

Concentrate safety and efficacy (English)

1 reference

3 August 2017

Kasper CK

1 reference

3 August 2017

publication date

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

161-165

1 reference

Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

Development and small-scale production of a severely heated factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

Human immunodeficiency virus infection due to clotting factor concentrates: results of the Seroconversion Surveillance Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

New-generation recombinant factor concentrates: bridge to gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

Potency estimation of recombinant factor VIII: effect of assay method and standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

Stability of factor VIII concentrates after reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00601.X

10.1046/J.1365-2516.2002.00601.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference